Moriwaki Mutsuko, Toba Mikayo, Takizawa Makiko, Shimizu Hiroaki, Tanaka Haruna, Takahashi Chihiro, Imai Shinobu, Kakehashi Masayuki, Fushimi Kiyohide
Quality Management Center, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan.
Quality Management Center, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan.
Int Dent J. 2025 May 9;75(4):100822. doi: 10.1016/j.identj.2025.04.003.
Oral bacteria influence bloodstream infections in hematopoietic stem cell transplantation (HSCT). We investigated the effects of oral health management and its relationship with medical care delivery systems.
Patients aged >16 years who underwent HSCT, discharged from Japanese acute care hospitals between April 2018 and March 2022, were categorized into autologous and allogeneic HSCT groups. Multivariable analysis assessed the impact of peri-HSCT oral management on antibiotic use, narcotic injections, and mortality rates.
We included 12,248 patients, 5936 autologous and 6312 allogeneic HSCT patients, across 298 hospitals. The defined daily dose (DDD) of antibiotic use within 14 days post-transplantation in the oral and nonoral management groups for allogeneic HSCT patients was 34.10 (standard deviation [SD] 20.35) vs 36.37 (SD 21.33); broad-spectrum antibiotics use was 23.87 (SD 15.82) vs 24.45 (SD 15.76). Within 30 days post-transplantation, the DDD of antibiotic use was 69.13 (SD 40.18) vs 75.16 (SD 43.47) was 45.70 (SD 29.63) vs 47.95 (SD 30.48), respectively. In allogeneic HSCT patients, oral management resulted in lower DDD of antibiotic use by 2.66 within 14 days and 6.74 within 30 days post-transplantation, after adjustment for relevant factors. Broad-spectrum antibiotic use within 30 days post-transplantation showed a lower DDD by 2.79 (P < .01). Narcotic use led to a 0.34 lower DDD (P < .01) within 14 days and 0.70 lower DDD (P < .01) within 30 days. In autologous HSCT patients, oral management did not affect the outcomes. The certification standard for unrelated HSCT, categorized into four classes (no certification and certification levels 1-3), was associated with an 8.41 point increase in hospital oral management implementation per class.
Ensuring an appropriate oral environment for allogeneic HSCT patients helps preventing infection, extending life expectancy, and alleviating pain.
Coordinated care between dental and medical teams is essential to deliver safe, personalized, and high-quality patient outcomes during HSCT.
口腔细菌会影响造血干细胞移植(HSCT)中的血流感染。我们研究了口腔健康管理的效果及其与医疗服务提供系统的关系。
2018年4月至2022年3月期间从日本急症医院出院的年龄大于16岁且接受HSCT的患者被分为自体HSCT组和异体HSCT组。多变量分析评估了HSCT围手术期口腔管理对抗生素使用、麻醉剂注射和死亡率的影响。
我们纳入了来自298家医院的12248例患者,其中5936例为自体HSCT患者,6312例为异体HSCT患者。异体HSCT患者移植后14天内,口腔管理组和非口腔管理组抗生素使用的限定日剂量(DDD)分别为34.10(标准差[SD]20.35)和36.37(SD 21.33);广谱抗生素使用量分别为23.87(SD 15.82)和24.45(SD 15.76)。移植后30天内,抗生素使用的DDD分别为69.13(SD 40.18)和75.16(SD 43.47),分别为45.70(SD 29.63)和47.95(SD 30.48)。在异体HSCT患者中,经相关因素调整后,口腔管理使移植后14天内抗生素使用的DDD降低2.66,30天内降低6.74。移植后30天内广谱抗生素使用的DDD降低2.79(P < 0.01)。麻醉剂使用使14天内DDD降低0.34(P < 0.01),30天内降低0.70(P < 0.01)。在自体HSCT患者中,口腔管理未影响结果。无关HSCT的认证标准分为四类(无认证和1 - 3级认证),每提高一级,医院口腔管理实施率增加8.41个百分点。
为异体HSCT患者确保适宜的口腔环境有助于预防感染、延长预期寿命和减轻疼痛。
牙科团队和医疗团队之间的协调护理对于在HSCT期间提供安全、个性化和高质量的患者治疗结果至关重要。